Chris Pasquale
Stock Analyst at Guggenheim
(n/a)
# 4,407
Out of 4,761 analysts
6
Total ratings
n/a
Success rate
-28.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Pasquale
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZIMV ZimVie | Initiates: Neutral | n/a | $13.31 | - | 1 | Mar 18, 2022 | |
| ICAD iCAD, Inc. | Downgrades: Neutral | n/a | $2.70 | - | 2 | Jan 18, 2022 | |
| DXCM DexCom | Upgrades: Buy | $145 | $88.78 | +63.33% | 1 | Jan 7, 2022 | |
| COO The Cooper Companies | Upgrades: Buy | $124 | $88.48 | +39.86% | 1 | Jan 3, 2022 | |
| PRCT PROCEPT BioRobotics | Initiates: Buy | $45 | $62.25 | -27.71% | 1 | Oct 11, 2021 |
ZimVie
Mar 18, 2022
Initiates: Neutral
Price Target: n/a
Current: $13.31
Upside: -
iCAD, Inc.
Jan 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.70
Upside: -
DexCom
Jan 7, 2022
Upgrades: Buy
Price Target: $145
Current: $88.78
Upside: +63.33%
The Cooper Companies
Jan 3, 2022
Upgrades: Buy
Price Target: $124
Current: $88.48
Upside: +39.86%
PROCEPT BioRobotics
Oct 11, 2021
Initiates: Buy
Price Target: $45
Current: $62.25
Upside: -27.71%